Clinical trial Recruiting at 30 sites Observational Ages 18 and up

China HEAD: a large community study on healthy aging and dementia

Official title: China HEalthy Aging and Dementia Study (HEAD)

Run by Fudan University · NCT07912710 · Data updated 2026-11-12

This study tests whether collecting health, imaging, and biospecimen data from adults in China can help predict who will develop Alzheimer’s disease and related dementias.

More Dementia trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment20000 (estimated)
SponsorFudan University
Academic / other
Locations30 sites (Beijing and 29 other locations)
StatusRecruiting
StartedAugust 1, 2022
Main results expectedAugust 1, 2072
Study endsAugust 1, 2072
Registry record updatedNovember 3, 2026
Trial IDNCT07912710 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 50–79 living in China who can participate in long-term follow-up and consent to biospecimen donation and data collection.

Probably not a fit

Individuals without risk factors or those unable to participate in long-term follow-up may derive limited or no direct benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The China HEAD study is a large, prospective, community-based cohort enrolling about 20,000 adults aged 50–79 across multiple regions in China. It collects detailed clinical data, cognitive assessments, physical measurements, biospecimens, and, when feasible, electrophysiology and imaging data to explore early signs of cognitive decline and ADRD. Participants are followed annually for up to 50 years to observe progression from normal cognition to MCI and dementia. The study has a biobank and multi-omics component to support future research and potential intervention studies. Ethical approval was obtained, and informed consent is collected at baseline.

Why it matters

Potential benefit: If successful, the study could enable earlier prediction and diagnosis of ADRD in Chinese populations, guiding prevention and intervention efforts.

How similar studies have gone: Previous international cohort studies have shown value in similar multi-omics and imaging approaches for predicting cognitive decline, though population-specific validation in China is central here.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

China HEAD Community Cohort:

1. Resident in a Chinese community.
2. Aged 50-79 years.
3. Have adequate vision and hearing (with glasses or hearing aids if necessary), and be able to walk, communicate, and complete study-related assessments (including questionnaires, physical examinations, neuropsychological assessments, and biospecimen collection) independently or with assistance.
4. Willing to provide written informed consent for baseline assessments, follow-up, biospecimen donation, and data collection.

China HEAD Familial Sub-cohort:

1. Resident in a Chinese community.
2. Aged 18 years or older.
3. Have a family history of Alzheimer's disease (AD) involving at least two first-degree relatives across at least two consecutive generations, with AD diagnoses previously established at tertiary hospitals and verified through medical history.
4. Meet the 2011 National Institute on Aging-Alzheimer's Association (NIA-AA) diagnostic criteria for AD.
5. Have adequate vision and hearing (with glasses or hearing aids if necessary), and be able to walk, communicate, and complete study-related assessments (including questionnaires, physical examinations, neuropsychological assessments, and biospecimen collection) independently or with assistance.
6. Willing to provide written informed consent for baseline assessments, follow-up, biospecimen donation, and data collection.

Exclusion Criteria:

The following exclusion criteria apply to participants in the HEAD study:

1. Refusal to provide written informed consent.
2. Refusal to participate in questionnaires or other data collection procedures.
3. Refusal to provide blood or other biological samples.
4. Self-reported stroke events (e.g., cerebral hemorrhage or cerebral infarction) within the past six months.
5. Self-reported diseases potentially impairing cognition, including congenital intellectual disability, intracranial tumors, epilepsy, Parkinson's disease, or severe psychiatric disorders such as schizophrenia requiring medication.
6. Self-reported major organ failure (e.g., liver or kidney failure), malignancy, or other conditions associated with a shortened life expectancy that prevent completion of follow-up assessments.

Additional exclusion criteria for participants undergoing magnetic resonance imaging (MRI):

1\. Inability to tolerate MRI examinations or contraindications to MRI, including claustrophobia; MRI-incompatible implanted pacemakers, aneurysm clips, artificial heart valves, cochlear implants, or other metallic implants; or other clinical conditions or examination findings that investigators consider potentially harmful during MRI.

Where it's running

  • Beijing Normal University
    Beijing, China
    Recruiting
  • Beijing Tiantan Hospital, Capital Medical University
    Beijing, China
    Recruiting
  • Beijing University of Posts and Telecommunications
    Beijing, China
    Recruiting
  • Chinese PLA General Hospital
    Beijing, China
    Recruiting
  • Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences
    Beijing, China
    Recruiting
  • Peking Union Medical College Hospital
    Beijing, China
    Recruiting
Show 24 more locations
  • Peking University
    Beijing, China
    Recruiting
  • Xuanwu Hospital, Capital Medical University
    Beijing, China
    Recruiting
  • Jilin University
    Changchun, China
    Recruiting
  • Sichuan University
    Chengdu, China
    Recruiting
  • Army Medical University, China
    Chongqing, China
    Recruiting
  • Fujian Medical University
    Fuzhou, China
    Recruiting
  • Southern Medical University
    Guangzhou, China
    Recruiting
  • Sun Yat-sen University
    Guangzhou, China
    Recruiting
  • The First Affiliated Hospital of University of Science and Technology of China
    Hefei, China
    Recruiting
  • Shandong First Medical University
    Jinan, China
    Recruiting
  • Southeast University, China
    Nanjing, China
    Recruiting
  • Qingdao University
    Qingdao, China
    Recruiting
  • Fudan University
    Shanghai, China
    Recruiting
  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, China
    Recruiting
  • Shanghai University
    Shanghai, China
    Recruiting
  • Tongji University
    Shanghai, China
    Recruiting
  • Shenzhen Bay Laboratory
    Shenzhen, China
    Recruiting
  • Shenzhen University
    Shenzhen, China
    Recruiting
  • Fudan University Taizhou Institute of Health Sciences
    Taizhou, China
    Recruiting
  • Tianjin Medical University
    Tianjin, China
    Recruiting
  • Wuhan University of Science and Technology
    Wuhan, China
    Recruiting
  • The First Affiliated Hospital of Xiamen University
    Xiamen, China
    Recruiting
  • Qinghai Provincial People's Hospital
    Xining, China
    Recruiting
  • Zhoukou Central Hospital
    Zhoukou, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns

    This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.

    Recruiting University of Cambridge · Cambridge, CB2 · NCT07786116

  • Cognition and Aging in China

    This study is trying to gather information from people in China with different types of dementia and mild cognitive impairment to better understand the condition and improve how it's diagnosed and treated.

    Recruiting at 65 sites Capital Medical University · Hefei, Anhui and 64 other locations · NCT03653156

  • Comprehensive assessment of neurodegeneration and dementia

    This project will collect brain scans, cognitive tests, and biological samples over time to see how dementia and related conditions progress in adults aged 50–90, including people with Parkinson's and people without cognitive problems.

    Recruiting at 11 sites McGill University · Calgary, Alberta and 18 other locations · NCT03402919

  • Aging Brain Health Initiative in Fujian

    This observational study will follow about 3,000 older adults in Fujian to see how Alzheimer's-related changes develop and to test new digital tests, biomarkers, and imaging tools for early diagnosis.

    Recruiting at 4 sites Fujian Medical University Union Hospital · Fushun, Fujian and 3 other locations · NCT07891429

  • Photobiomodulation therapy for mild cognitive impairment and mild Alzheimer's disease

    This trial tests whether daily transcranial near-infrared light therapy, versus a sham device, can improve cognitive function in adults with mild cognitive impairment or mild Alzheimer's disease.

    Recruiting Beijing Tiantan Hospital · Beijing · NCT07835399

  • Gut and Oral Microbiome and Cognitive Health in Aging

    This study tests whether differences in gut and mouth bacteria are linked to cognitive health in adults across ages and cognitive status.

    Recruiting University of South Florida · Tampa, Florida · NCT07799402

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.